Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib

被引：0
|
作者：
Yu, Helena Alexandra
Kerr, Keith
Rolfo, Christian Diego
Fang, Jian
Finocchiaro, Giovanna
Wong, Kam-Hung
Veillon, Remi
Kato, Terufumi
Yang, James Chih-Hsin
Nadal, Ernest
Raskin, Jo
Le, Xiuning
Karachaliou, Niki
Ellers-Lenz, Barbara
OBrate, Aurora
Stroh, Christopher
Piske, Nadine
Boesler, Carsten
Yang, Jinji
Mazieres, Julien
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Aberdeen, Sch Med, Dept Pathol, Aberdeen, Scotland
[3] Aberdeen Royal Infirm, Aberdeen, Scotland
[4] Mt Sinai Med Syst, Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA
[5] Icahn Sch Med, New York, NY USA
[6] Peking Univ Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[7] IRCCS Humanitas Res Hosp, Milan, Italy
[8] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[9] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[10] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[11] Natl Taiwan Univ, Ctr Canc, Dept Med Oncol, Taipei, Taiwan
[12] Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain
[13] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium
[14] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[15] Merck KGaA, Healthcare Business, Global Clin Dev, Darmstadt, Germany
[16] Merck KGaA, Healthcare Business, Dept Biostat, Darmstadt, Germany
[17] Merck KGaA, Healthcare Business, Global Med Affairs, Darmstadt, Germany
[18] Merck KGaA, Healthcare Business, Compan Diagnost & Biomarker Strategy, Darmstadt, Germany
[19] Merck KGaA, Healthcare Business, Clin Biomarkers & Technol, Darmstadt, Germany
[20] Guangdong Gen Hosp & Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Dept Oncol, Guangzhou, Peoples R China
[21] Univ Paul Sabatier, CHU Toulouse, Toulouse, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9074
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
    Tan, Daniel Shao-Weng
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen
    Chia, Puey Ling
    De Marinis, Filippo
    Le, Xiuning
    Karachaliou, Niki
    Brutlach, Sabine
    Adrian, Svenja
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [3] Tepotinib plus osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
    Mazieres, J.
    Kim, T. M.
    Lim, B. K.
    Wislez, M.
    Dooms, C.
    Finocchiaro, G.
    Hayashi, H.
    Liam, C. K.
    Raskin, J.
    Tho, L. M.
    de Marinis, F.
    Nadal, E.
    Smit, E.
    Le, X.
    Brutlach, S.
    Grupp, A. M. O'Brate
    Adrian, S.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1419 - S1420
  • [4] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [5] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
    Smit, E. F.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
  • [6] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [7] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, T. M.
    Guarneri, V.
    Jye, V. P.
    Khaw, L. B.
    Yang, J. -J.
    Wislez, M.
    Huang, C.
    Kin, L. Chong
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nhung, N.
    Chia, P. L.
    De Marinis, F.
    Raskin, J.
    Zhou, Q.
    Finochhiaro, G.
    Le, X.
    Tan, D.
    Brutlach, S.
    O'Brate, A.
    Adrian, S.
    Berghoff, K.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
  • [8] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jin-ji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Ye Mun
    Hayashi, Hidetoshi
    Nhung Nguyen
    Chia, Puey Ling
    de Marinis, Filippo
    Raskin, Jo
    Zhou, Qinghua
    Finocchiaro, Giovanna
    Le, Xiuning
    Tan, Daniel
    O'Hara, Richard M., Jr.
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E38 - E38
  • [9] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [10] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
12345